Cleveland Clinic Abu Dhabi Performs UAE's First Cryoneurolysis for MS Spasticity

Cleveland Clinic Abu Dhabi announced it performed the United Arab Emirates' first cryoneurolysis procedure for spasticity, treating a 36-year-old patient with multiple sclerosis (MS) whose leg stiffness had not adequately responded to standard treatments. The hospital is currently the sole provider of this treatment for spasticity in the country.

Context

Multiple sclerosis is a chronic disease that affects the central nervous system, often leading to symptoms such as muscle stiffness and spasticity. Traditional treatments may not be effective for all patients, leaving a gap in care options. Cryoneurolysis is a minimally invasive procedure that uses extreme cold to disrupt nerve signals, providing relief from spasticity.

Why it matters

The introduction of cryoneurolysis for treating spasticity represents a significant advancement in the management of multiple sclerosis in the UAE. This procedure offers a new option for patients who have not responded to traditional treatments, potentially improving their quality of life. As the sole provider of this treatment in the country, Cleveland Clinic Abu Dhabi is positioned to lead in innovative MS care.

Implications

If cryoneurolysis proves effective, it could change the treatment landscape for multiple sclerosis in the UAE, offering hope to many patients. This may also lead to increased demand for advanced neurological treatments in the region. Healthcare policies may evolve to incorporate innovative procedures, impacting how MS is managed nationally.

What to watch

The response of patients to cryoneurolysis will be closely monitored, particularly its effectiveness and any potential side effects. Cleveland Clinic Abu Dhabi may expand its offerings based on initial outcomes and patient feedback. Additionally, other healthcare providers in the UAE might consider adopting similar treatments if proven successful.